Aprea Therapeutics Q1 2023 Earnings Report $3.08 -0.26 (-7.78%) (As of 12/18/2024 05:44 PM ET) Earnings HistoryForecast Aprea Therapeutics EPS ResultsActual EPS-$1.34Consensus EPS -$1.51Beat/MissBeat by +$0.17One Year Ago EPSN/AAprea Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAprea Therapeutics Announcement DetailsQuarterQ1 2023Date5/15/2023TimeN/AConference Call ResourcesAPRE Earnings History URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Aprea Therapeutics Earnings HeadlinesAprea Therapeutics (NASDAQ:APRE) Receives "Buy" Rating from HC WainwrightDecember 19 at 2:50 AM | americanbankingnews.comPromising Clinical Advances Drive Buy Rating for Aprea TherapeuticsDecember 17 at 2:11 PM | markets.businessinsider.comI want to send you my Cash CalendarThis Calendar reveals the EXACT dates that — if everything goes right — anyone can target cash payouts of $125, $415, and even $1,665. (With just a $1,000 starting stake!) Granted, there were smaller wins and those that did not work out and we cannot promise future returns or against losses, but these payouts don’t require any special knowledge or skills. Anyone can set them up with just three clicks in their brokerage account. And the money can be deposited in their account the very next morning after opening the trade. Again, I want to send this Cash Calendar to you completely FREE. All you have to do is join me for my free Cash Calendar training right here. You don’t want to miss this. There is a very special bonus surprise for everyone who attends. December 19, 2024 | Wealthpin Pro (Ad)Aprea Therapeutics’ Promising ATRN-119: A Buy Rating Amid Optimized Dosing and Safety AdvancementsDecember 13, 2024 | markets.businessinsider.comAprea Therapeutics Updates ABOYA-119 Trial with Twice Daily DosingDecember 13, 2024 | msn.comAprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path ForwardDecember 11, 2024 | globenewswire.comSee More Aprea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aprea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aprea Therapeutics and other key companies, straight to your email. Email Address About Aprea TherapeuticsAprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.View Aprea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
